Table 1.
Patient demographic information.
| Demographics | Total (n = 2,802) |
|---|---|
| Male, n (%) | 1,688 (60.2) |
| Age (years), mean (sd) | 60.74 (10.91) |
| White or Caucasians, n (%) | 2,611 (93.2) |
| BSA, mean (sd) | 1.87 (0.24) |
| LDH baseline ≥1.5 UNL, n (%) | 836 (29.8) |
| ECOG performance, n (%) | |
| 0 | 1,536 (54.8) |
| 1 | 1,178 (42.0) |
| 2 | 87 (3.2) |
| KRAS status, n (%) | |
| Wild-type | 795 (28.4) |
| Mutant | 593 (21.2) |
| Unknown | 1,414 (50.4) |
| Primary tumor type, n (%) | |
| Colon | 1910 (68.2) |
| Rectum | 892 (31.8) |
| Number of metastatic sites, n (%) | |
| 1 | 382 (13.6) |
| 2 | 449 (16.0) |
| ≥3 | 1971 (70.4) |
| Liver-metastases only, n (%) | 1347 (48.1) |
| Prior surgery, n (%) | 2535 (90.5) |
| Prior radiation therapy, n (%) | 367 (13.1) |
| Previous adjuvant therapy, n (%) | 505 (18.0) |
| RECIST response, n (%) | |
| Complete response | 77 (2.7) |
| Partial response | 1,069 (38.2) |
| Stable disease | 1,173 (41.9) |
| Progressive disease | 401 (14.3) |
| Not detected | 31 (1.2) |
| Unable evaluate | 39 (1.4) |
| Unknown | 12 (0.3) |
| Treatment, n (%) | |
| Bevacizumab plus chemotherapy | 377 (13.5) |
| Bevacizumab plus panitumumab plus chemotherapy | 371 (13.2) |
| FOLFIRI | 419 (15.0) |
| Panitumumab plus FOLFIRI | 425 (15.2) |
| FOLFOX | 769 (27.4) |
| Panitumumab plus FOLFOX | 441 (15.7) |